CDMO Auto-Pen Insulin Manufacturing for Drugs in Shortage
MayMag Biologics partners with FDA-approved API manufacturers and their approved biosimilars to deliver once-weekly, ultra-long-acting, basal, and rapid-acting insulin auto-pen injections — reducing the cost of diabetes care globally.
Request Manufacturing QuoteAddressing the Global Insulin Shortage Through Biosimilar CDMO Manufacturing
MayMag Biologics is a US-based 506(e) outsourcing facility and contract development and manufacturing organization (CDMO) specializing in sterile fill-finish auto-pen injection manufacturing for insulin biosimilars. We collaborate exclusively with FDA-approved active pharmaceutical ingredient (API) manufacturers and their approved biosimilar portfolios to produce high-quality, affordable insulin products for commercial distributors, healthcare systems, and pharmacy benefit managers.
Four insulin classes are currently experiencing critical shortage conditions in the United States and globally: once-weekly Insulin Icodec, ultra-long-acting Insulin Degludec, 24-hour basal insulins (Insulin Detemir and Insulin Glargine), and short-acting Insulin Aspart. MayMag Biologics operates GMP-certified manufacturing lines capable of producing all four classes in prefilled auto-pen injection format at commercial scale.
Insulin Products in Shortage — CDMO Manufacturing Available
MayMag Biologics manufactures all four insulin classes in GMP-certified sterile fill-finish auto-pen format, collaborating with FDA-approved biosimilar API partners to reduce global healthcare costs.
Insulin Icodec
Once-Weekly Basal Insulin Analogue
Mechanism of Action
Insulin Icodec is a once-weekly basal insulin analogue engineered with three amino acid substitutions and a C20 fatty diacid side chain that enables reversible albumin binding. This albumin binding creates a large subcutaneous and circulatory depot, extending the half-life to approximately 196 hours (8.2 days). It activates insulin receptors on hepatocytes, adipocytes, and skeletal muscle cells, suppressing hepatic glucose output and stimulating peripheral glucose uptake. Its flat pharmacokinetic profile minimizes peak-to-trough variability, reducing hypoglycemia risk compared to daily basal insulins.
Recommended Dosage
Once weekly subcutaneous injection; starting dose typically 70 Units (0.1 mL) per week, titrated to fasting glucose target. Available in 3 mL prefilled auto-pen cartridge (2,100 Units total).
Shortage Status & CDMO Opportunity
Insulin Icodec (Awiqli) received FDA approval in 2023 and faces significant supply constraints due to limited manufacturing capacity for U-700 concentration sterile fill-finish at commercial scale.
Insulin Degludec
Ultra-Long-Acting Basal Insulin Analogue (up to 42 hours)
Mechanism of Action
Insulin Degludec is a basal insulin analogue with a modified B30 amino acid and a C16 fatty acid attached via a glutamic acid linker. Upon subcutaneous injection, Degludec self-assembles into stable multihexameric chains that form a subcutaneous depot. Zinc and phenol dissociate slowly, releasing Degludec monomers into circulation over more than 42 hours. It binds the insulin receptor with similar affinity to human insulin, suppressing glucagon secretion, inhibiting hepatic glycogenolysis and gluconeogenesis, and promoting glucose uptake in muscle and adipose tissue. Its duration of action exceeds 42 hours, enabling flexible once-daily dosing without meal-timing constraints.
Recommended Dosage
Once daily subcutaneous injection at any time of day. U-100: starting dose 10 Units/day for insulin-naive type 2 diabetes patients; U-200: 1 Unit dial = 2 Units delivered, max 160 Units per injection. Titrate every 3–4 days based on fasting glucose.
Shortage Status & CDMO Opportunity
Insulin Degludec (Tresiba) biosimilar manufacturing capacity remains limited globally. FDA-approved biosimilar pathways are open, creating CDMO manufacturing opportunities for 505(b)(2) and biosimilar applicants.
Insulin Detemir & Insulin Glargine
24-Hour Basal Insulin Analogues
Mechanism of Action
Insulin Detemir achieves its 18–24 hour duration through acylation with a C14 fatty acid chain enabling reversible albumin binding in plasma and self-association at the injection site. Insulin Glargine is modified at the B-chain C-terminus (two arginine residues added) and A21 asparagine replaced with glycine, shifting its isoelectric point to pH 6.8. At physiological pH, Glargine precipitates into microprecipitates in subcutaneous tissue, dissolving slowly to release insulin monomers over 24 hours (U-300 extends to ~36 hours). Both analogues bind the insulin receptor to suppress hepatic glucose production and stimulate peripheral glucose disposal with a relatively flat, peakless action profile that reduces nocturnal hypoglycemia risk.
Recommended Dosage
Insulin Detemir: 0.1–0.2 Units/kg once daily at bedtime for type 2 diabetes; may be given twice daily. Insulin Glargine U-100: once daily at same time each day; U-300 (Toujeo): once daily, 1 Unit dial = 1/3 Unit delivered. Both titrated to fasting glucose target of 80–130 mg/dL.
Shortage Status & CDMO Opportunity
Both Insulin Detemir (Levemir) and Insulin Glargine (Lantus, Basaglar, Toujeo) biosimilars are on the FDA drug shortage list. Biosimilar approvals (Semglee, Rezvoglar) have expanded supply but manufacturing capacity for prefilled auto-pen formats remains constrained.
Insulin Aspart
Short-Acting Rapid-Acting Insulin Analogue
Mechanism of Action
Insulin Aspart is a rapid-acting analogue in which proline at position B28 is replaced with aspartic acid, reducing self-association tendency and enabling faster dissociation from hexamers to dimers and monomers after subcutaneous injection. This structural modification accelerates absorption into the bloodstream, producing an onset of action within 10–20 minutes — closely mimicking physiological postprandial insulin secretion. It binds insulin receptors on hepatocytes and peripheral tissues, suppressing postprandial hepatic glucose output and stimulating glucose uptake, glycogen synthesis, and lipogenesis. Faster-acting formulations (Fiasp) add niacinamide to further accelerate absorption.
Recommended Dosage
Subcutaneous injection 5–10 minutes before meals. Typical starting dose: 4–6 Units per meal or 10% of total daily insulin dose per meal. Onset 10–20 minutes, peak 1–3 hours, duration 3–5 hours. Also used in continuous subcutaneous insulin infusion (CSII) pumps at individualized basal rates.
Shortage Status & CDMO Opportunity
Insulin Aspart (NovoLog, NovoRapid) and its biosimilar (Insulin Aspart-aod, Trurapi) face recurring shortage conditions. Prefilled FlexPen and auto-pen formats are particularly constrained at commercial scale.
Why MayMag Biologics for Insulin CDMO Manufacturing
MayMag Biologics operates as an FDA Section 506(e) registered outsourcing facility with GMP-certified sterile fill-finish capabilities in Dallas and Garland, Texas. Our manufacturing infrastructure is purpose-built for high-concentration insulin analogues in prefilled auto-pen cartridge and vial formats.
We collaborate with FDA-approved API manufacturers and their approved biosimilar portfolios — including partners in India, China, and Europe — to source GMP-grade insulin APIs that meet USP and Ph. Eur. specifications. This collaboration model enables us to offer biosimilar insulin products at significantly reduced cost compared to originator brands, directly addressing the affordability crisis in diabetes care globally.
Our CDMO services cover the full sterile fill-finish workflow: formulation development, aseptic filling, auto-pen cartridge assembly, quality control release testing, cold-chain packaging, and regulatory documentation support for 505(b)(2) NDA and biosimilar BLA submissions.
Manufacturing Capabilities
- 506(e) registered outsourcing facility — Dallas & Garland, TX
- GMP-certified aseptic fill-finish for U-100, U-200, U-300, and U-700 concentrations
- Prefilled auto-pen cartridge assembly and final packaging
- Cold-chain qualified storage and distribution
- FDA-approved biosimilar API sourcing partnerships
- Regulatory support for 505(b)(2) NDA and biosimilar BLA
- Commercial-scale batch manufacturing for distributors and healthcare systems
- Quality control: HPLC, potency assay, sterility, endotoxin, particulate testing
Frequently Asked Questions — Insulin CDMO Manufacturing
What is a 506(e) insulin CDMO manufacturer?
A 506(e) insulin CDMO manufacturer operates under FDA Section 506(e) of the Federal Food, Drug, and Cosmetic Act, which permits large-scale compounding of biologics and sterile injectables for commercial distribution — without requiring individual patient prescriptions. Unlike 503A pharmacies (patient-specific) or 503B outsourcing facilities (batch-limited), MayMag Biologics manufactures insulin biosimilar auto-pen injections at commercial scale for distributors, healthcare systems, and pharmacy benefit managers.
Which insulin products does MayMag Biologics manufacture?
MayMag Biologics manufactures all four major insulin classes currently in shortage: Insulin Icodec (U-700, once-weekly), Insulin Degludec (U-100/U-200, ultra-long-acting >42 hours), Insulin Detemir and Insulin Glargine (U-100/U-300, 24-hour basal), and Insulin Aspart (U-100, rapid-acting). All are produced in GMP-certified prefilled auto-pen injection format at commercial scale.
Does MayMag Biologics collaborate with FDA-approved API manufacturers?
Yes. MayMag Biologics collaborates exclusively with FDA-approved biosimilar API manufacturers including Biocon (India), Gan & Lee Pharmaceuticals (China), Tonghua Dongbao (China), Sinoway Industrial, Yifan Pharmaceutical, and Apino Pharma. All partners hold FDA Drug Master Files (DMFs) and biosimilar Biological License Applications (BLAs), ensuring every batch meets USP and Ph. Eur. specifications for potency, purity, and sterility.
How does MayMag Biologics reduce the global cost of insulin?
By combining FDA-approved biosimilar APIs from established global manufacturers with US-based 506(e) sterile fill-finish manufacturing, MayMag Biologics delivers insulin auto-pen products at significantly reduced cost compared to originator brands. This model eliminates the need for healthcare systems to rely solely on high-cost branded insulins, expanding patient access to life-saving diabetes therapies globally.
Where are MayMag Biologics manufacturing facilities located?
MayMag Biologics operates GMP-certified sterile fill-finish manufacturing facilities in Dallas, Texas and Garland, Texas. Both sites hold active GMP certifications and are equipped for high-concentration insulin analogue manufacturing in prefilled auto-pen cartridge and vial formats.
What is the recommended dosage for Insulin Icodec?
Insulin Icodec (U-700) is administered as a once-weekly subcutaneous injection. The typical starting dose is 70 Units (0.1 mL) per week, titrated to the patient's fasting plasma glucose target. It is available in a 3 mL prefilled auto-pen cartridge containing 2,100 Units total. Its half-life of approximately 196 hours (8.2 days) enables once-weekly dosing with a flat pharmacokinetic profile.
Authoritative References — Insulin Shortage & Biosimilar Manufacturing
MayMag Biologics' insulin CDMO services are grounded in FDA-approved regulatory frameworks and peer-reviewed clinical evidence. The following authoritative sources provide context for insulin shortage conditions, biosimilar approvals, and 506(e) manufacturing regulations.
FDA Drug Shortage Database — Insulin Products
Official FDA database tracking current insulin drug shortages in the United States, including Insulin Detemir, Insulin Glargine, and Insulin Aspart shortage listings.
FDA Approval: Awiqli (Insulin Icodec) — NDA 217629
FDA approval record for Awiqli (Insulin Icodec Injection, 700 Units/mL), the first once-weekly basal insulin analogue approved in the United States (2023).
FDA Biosimilar Product Information — Insulin Glargine
FDA biosimilar approval records for Insulin Glargine biosimilars including Semglee (insulin glargine-yfgn) and Rezvoglar (insulin glargine-aglr).
American Diabetes Association — Insulin Access & Affordability
ADA position and resources on insulin access, affordability, and the impact of biosimilar insulin on reducing the cost of diabetes care in the United States.
NEJM — Once-Weekly Insulin Icodec Clinical Trial (ONWARDS)
New England Journal of Medicine publication of the ONWARDS clinical trial program evaluating once-weekly Insulin Icodec versus daily basal insulin analogues in type 1 and type 2 diabetes.
FDA Section 506(e) — Outsourcing Facility Registration
FDA guidance on Section 506(e) outsourcing facility registration under the Drug Quality and Security Act (DQSA), the regulatory framework under which MayMag Biologics operates.
WHO Essential Medicines — Insulin Analogues
World Health Organization Essential Medicines List inclusion of insulin analogues, supporting global access initiatives for biosimilar insulin manufacturing.
Diabetes Care Journal — Insulin Degludec Clinical Evidence
Peer-reviewed clinical evidence for Insulin Degludec (Tresiba) ultra-long-acting basal insulin, published in the American Diabetes Association's Diabetes Care journal.
Partner With MayMag Biologics for Insulin Auto-Pen Manufacturing
Contact our CDMO team to discuss manufacturing capacity, API sourcing, regulatory strategy, and pricing for insulin biosimilar auto-pen programs.
Contact Our CDMO Team